# PRISMA–P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA–P) 2015 statement. *Systematic Reviews* 2015 4:1

| Section/topic | # | Checklist item | Information reported | Line number(s) |
|---------------|---|----------------|----------------------|----------------|
| **ADMINISTRATIVE INFORMATION** | | | | |
| Title | Identification | 1a | Identify the report as a protocol of a systematic review | √ | No | Title, 1 |
| | Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | No | | Not applicable |
| | Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | √ | No | 36, 103-104 (PROSPERO CRD42019145834) |
| Authors | Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | √ | No | title page |
| | Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | √ | No | title page |
| | Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | No | | Not applicable |
| Support | Sources | 5a | Indicate sources of financial or other support for the review | No | | Not applicable |
| | Sponsor | 5b | Provide name for the review funder and/or sponsor | No | | Not applicable |
| | Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | No | | Not applicable |
| **INTRODUCTION** | | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | √ | No | 9-13 & 41-91 |
| Section/topic               | # | Checklist item                                                                 | Information reported | Line number(s) |
|----------------------------|---|--------------------------------------------------------------------------------|----------------------|----------------|
| **Objectives**             | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | √                    | 96-100         |
| **METHODS**                |   |                                                                                  |                      |                |
| Eligibility criteria       | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | √                    | 108-169        |
| Information sources        | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | √                    | 171-185        |
| Search strategy            | 10| Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | √                    | Additional file#2 |
| **STUDY RECORDS**         |   |                                                                                  |                      |                |
| Data management            | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | √                    | 188-199        |
| Selection process          | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | √                    | 191-199        |
| Data collection process    | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | √                    | 202-213        |
| Data items                 | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | √                    | 204-212        |
| Outcomes and prioritization| 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | √                    | 141-153        |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | √                    | 216-222        |
| **DATA**                  |   |                                                                                  |                      |                |
| Synthesis                  | 15a| Describe criteria under which study data will be quantitatively synthesized | √                    | 225-226        |
| Section/topic               | #  | Checklist item                                                                 | Information reported | Line number(s) |
|----------------------------|----|---------------------------------------------------------------------------------|----------------------|----------------|
|                            |    |                                                                                 | Yes | No |                      |
| **15b**                    | 15b| If data are appropriate for quantitative synthesis, describe planned summary    | √   | No | 227-240              |
|                            |    | measures, methods of handling data, and methods of combining data from          |                      |                |
|                            |    | studies, including any planned exploration of consistency (e.g., $I^2$,        |                      |                |
|                            |    | Kendall’s tau)                                                                  |                      |                |
|                            | 15c| Describe any proposed additional analyses (e.g., sensitivity or subgroup        | √   | No | 240-242              |
|                            |    | analyses, meta-regression)                                                       |                      |                |
|                            | 15d| If quantitative synthesis is not appropriate, describe the type of summary      | √   | No | 242-244              |
|                            |    | planned                                                                       |                      |                |
| **Meta-bias(es)**          | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias        | √   | No | 251-257              |
|                            |    | across studies, selective reporting within studies)                            |                      |                |
| **Confidence in cumulative evidence** | 17| Describe how the strength of the body of evidence will be assessed (e.g.,     | √   | No | 259-262              |
|                            |    | GRADE)                                                                         |                      |                |